This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
After a strong pre-season, Melksham had strong form during the 2012 NAB Cup, which led to former Essendon player and The Age journalist, Matthew Lloyd naming Melksham as one of the players who would have a breakout season. After the club had an outstanding start to the season where the team won eight out of nine matches, with the only loss being one point to Collingwood in the Anzac Day clash; hype surrounding the club was immense with 1987 premiership coach, Robert Walls denoting the club could win a premiership, indicating the improvement of the players, especially Melksham, was one of the reasons for a potential flag. Garry Lyon also noted the improvement of Melksham as one of the reasons for Essendon's strong start to the season, along with The Age journalist, Martin Flanagan, praising Melksham and his contribution to the club's fortunes. After round nine, the club lost ten of the final thirteen matches, including the final seven to finish outside of the top eight; the decline in the teams' performance saw Melksham's form dip as well, with The Age journalist, Rohan Connolly stating Melksham's development had "stalled". Despite being one of two players to play every match during the season, he failed to finish inside the top ten in the club best and fairest.
== Medical uses == In the US, crisaborole is indicated for topical treatment of mild to moderate atopic dermatitis in people three months of age and older. In the EU, crisaborole was authorized for treatment of mild to moderate atopic dermatitis in people two years of age and older with ≤ 40% body surface area (BSA) affected.
The Sanders campaign was bolstered by a wave of optimistic volunteers as well as a series of endorsements from university professors, social welfare agencies, and the police union. The result shocked the local political establishment. Sanders formed a coalition of independents and the Citizens Party. On December 3, 1982, he announced that he would seek reelection. On January 22, 1983, the Citizens Party voted unanimously to endorse Sanders, although Sanders ran as an independent. He was reelected, defeating Judy Stephany and James Gilson. Sanders initially considered not seeking a third term, but announced on December 5, 1984, that he would run. He formally launched his campaign on December 7 and was reelected. On December 1, 1986, Sanders, who had finished third in the 1986 Vermont gubernatorial election, announced that he would seek reelection to a fourth term as mayor of Burlington, despite close associates saying that he was tired of being mayor. Sanders defeated Democratic nominee Paul Lafayette in the election. He said he would not seek another mayoral term after the 1987 election: "eight years is enough and I think it is time for new leadership, which does exist within the coalition, to come up". Sanders did not run for a fifth term as mayor. He went on to lecture in political science at Harvard Kennedy School that year and at Hamilton College in 1991.
Sources: en.wikipedia.org
East Point's Greatest Hit is the only solo studio album by American rapper Cool Breeze. It was released on March 23, 1999, via Organized Noize/A&M Records. The recording sessions took place at the Dungeon Recording Studio, the Chamber Recording Studios and Purple Dragon Recording Studios in SWATS, Sound Chamber Recorders in Los Angeles and the Boom Boom Room in Augusta. It was produced by Organized Noize, Mr. DJ, 2 Cold Capone and Skinny Miracles. It features guest appearances from Witchdoctor, 8Ball, Backbone, Big Rube, Goodie Mob, Kurupt, Nivea, Outkast, Sleepy Brown and the Calhouns. The album peaked at number 38 on the Billboard 200 and number 11 on the Top R&B/Hip-Hop Albums in the United States. Its lead single, a Dungeon Family posse cut "Watch for the Hook", made it to No. 73 on the US Billboard Hot 100.
=== Chemically modified dextran microspheres === Microspheres can also be developed by chemically modifying dextran. Acetated dextran can be modified with amine groups and grafted with heparin to form microspheres that provide protamine-stimulated, targeted drug release for the delivery of therapeutics to treat cardiovascular diseases. Dextran modified with an octyl- group creates microspheres that provide extended release of doxorubicin, which is an antitumor therapeutic.
=== Grenades === No. 36M HE Hand Grenade – In use until the 1970s No. 75 HE Hand Grenade No. 82 HE Hand Grenade No. 94 Anti-Tank Grenade - for use with the Lee-Enfield and then the L1A1. L2A1/A2 HE Hand Grenade – mid-1960s replacement for the Mills bomb. No. 80 Mk 1 White Phosphorus Smoke Hand Grenade No. 83 Mk 1-Mk 3 Coloured/Signal Smoke Hand Grenade series L35-L38 Signal Smoke Hand Grenade series L52-L55 Signal Smoke Hand Grenade series L64-L67 Signal Smoke Hand Grenade series
For services to the community in the area of Manningtree, Essex. Margaret Helena Booth. For political service. Patricia Mary Bottrill, Department Head (Ambulatory Care), Royal Victoria Infirmary, Newcastle-Upon-Tyne. For services to Health Care. Ruth Olive Boult. For services to the community in Messingham, South Humberside. Keith Du Brettargh Bowen. For services to disabled people in Leeds, West Yorkshire. Arthur Thomas Bowley. For services to the community in Brecon, Powys. The Reverend Father William Boyd, Officiating Chaplain, British Forces Rheindahlen. For services to the Armed Forces. John James Brady. For services to the Employment Service in Hebburn, Tyne and Wear. John Michael Brannon, Chairman, PMI Food Group UK, Foster Refrigerator Group of Companies. For services to Export. William Bratty. For charitable services to the community in Perth. Barbara Brewster, Personal Secretary, Board of Inland Revenue. Jean Brinkworth. For services to Guiding, particularly the Ranger Section, in the former South Glamorgan. Margaret Aline Jessica Brockbank. For services to the community in Bournemouth, Dorset. Wilfred Brockway. For services to the community in Fontmell Magna, Dorset. Cyril Albert Broom. For services to Legal Education. Barbara Brown. For political service. Jack Watson Brown. For political and public service. John Stuart Brown, General Medical Practitioner, Larkfield, Kent. For services to Medicine. Ronald Ezekiel Browne, Member, London Borough of Hammersmith and Fulham. For services to Local Government. Roger Ian Bryant.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.